arrow
A

Alison M. Elliott

medical research council and uganda virus research institute
H指数:62
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Extensive parasite transmission and variation in a functional receptor associated with drug resistance in endemic Schistosoma mansoni

在地方性曼氏血吸虫病中,与药物抗性相关的功能受体广泛传播及其变异

2026-07-170
OA
African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children

非洲特异性的遗传位点决定非洲儿童中铁状况以及重症疟疾和菌血症的风险。

2026-04-070
OAAI
Life Course Malaria Exposure and SARS-CoV-2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort

乌干达青少年生命历程疟疾暴露与SARS-CoV-2血清流行病学研究:一项基于出生队列的纵向研究

2026-04-010
OAAI
Temporal modulation of gene expression in a controlled Schistosoma mansoni human infection model

在受控的Schistosoma mansoni人体感染模型中基因表达的时序调控

2025-12-160
OAAI
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial

乌干达健康成人中ChAdOx1 RVF疫苗预防裂谷发热的安全性、耐受性和免疫原性: 一项单中心、单盲、随机、安慰剂对照、剂量递增、1期试验

2025-11-110
OAAI
T cell responses in repeated controlled human schistosome infection compared to natural exposure

Driciru, E.; Koopman, J.P.R.; Steenbergen, S.; Sonnet, F.; Stam, K.A.; Bes-Roeleveld, L.; Iliopoulou, E.; Janse, J.J.; Sijtsma, J.; Nambuya, I.; et al. T细胞反应在重复控制的类人血吸虫感染与自然暴露的比较。Nat. Commun. 2025, 16, 6827. [Google Scholar] [CrossRef]

2025-07-240
OAAI
Safety and efficacy of praziquantel 40 mg/kg versus 80 mg/kg in preschool-aged children with intestinal schistosomiasis in Uganda: a 2 × 2 factorial, double-blind, placebo-controlled, phase 2 randomised trial

在乌干达患有无肠道血吸虫病的学龄前儿童中,40 mg/kg与80 mg/kg吡喹酮的安全性和有效性比较:一项2×2析因、双盲、安慰剂对照、2期随机试验

2025-05-210
PRE
COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda

乌干达出现COVID-19样症状患者中的疫苗接种状况及影响因素

Vaccine
IF3.5
2025-03-070
OAAI
Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda

乌干达症状性COVID-19患者中,COVID-19疫苗对SARS-CoV-2感染的预防效果

Vaccine
IF3.5
2025-03-060
OAAI
Enterococcus and Eggerthella species are enriched in the gut microbiomes of COVID-19 cases in Uganda
2025-02-040
OAAI
Interdisciplinary symposium on challenges and opportunities for vaccines: A comprehensive approach of current and future vaccine strategies to improve vaccine effectiveness in complex chronic infectious contexts

跨学科研讨会:疫苗的挑战与机遇——当前及未来疫苗策略的综合方法,以提升复杂慢性感染背景下的疫苗效果

vaccine
IF2.2
2025-02-010
OAAI
Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination

新型冠状病毒肺炎疫苗接种时代乌干达新出现的SARS-CoV-2变异

2024-11-290
OAAI
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response

高分辨率非洲HLA资源揭示了疫苗反应背后的HLA-DRB1表达效应

2024-05-130
OAAI